Publicaciones en las que colabora con José Luis Pérez Gracia (31)

2024

  1. Dendritic Cells in Cancer Immunology and Immunotherapy

    Cancers, Vol. 16, Núm. 5

  2. Whole exome sequencing and machine learning germline analysis of individuals presenting with extreme phenotypes of high and low risk of developing tobacco-associated lung adenocarcinoma

    eBioMedicine, Vol. 102

2020

  1. Short-term starvation reduces IGF-1 levels to sensitize lung tumors to PD-1 immune checkpoint blockade

    Nature cancer, Vol. 1, Núm. 1, pp. 75-85

2018

  1. Genomic characterization of individuals presenting extreme phenotypes of high and low risk to develop tobacco-induced lung cancer

    Cancer Medicine, Vol. 7, Núm. 7, pp. 3474-3483

2014

  1. Serum interleukin-8 reflects tumor burden and treatment response across malignancies of multiple tissue origins

    Clinical Cancer Research, Vol. 20, Núm. 22, pp. 5697-5707

2013

  1. A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C

    Journal of Hepatology, Vol. 59, Núm. 1, pp. 81-88

  2. Investigation of complement activation product C4d as a diagnostic and prognostic biomarker for lung cancer

    Journal of the National Cancer Institute, Vol. 105, Núm. 18, pp. 1385-1393

2012

  1. The HIF-1α hypoxia response in tumor-infi ltrating T lymphocytes induces functional CD137 (4-1BB) for immunotherapy

    Cancer Discovery, Vol. 2, Núm. 7, pp. 608-623

2011

  1. Agonist anti-CD137 mAb act on tumor endothelial cells to enhance recruitment of activated T lymphocytes

    Cancer Research, Vol. 71, Núm. 3, pp. 801-811

  2. Assessment of epidermal growth factor receptor and krasmutation status in cytological stained smears of non-small celllung cancer patients: Correlation with clinical outcomes

    Oncologist, Vol. 16, Núm. 6, pp. 877-885

  3. Carcinoma-derived Interleukin-8 disorients dendritic cell migration without impairing T-cell stimulation

    PLoS ONE, Vol. 6, Núm. 3

  4. Dendritic cells take up and present antigens from viable and apoptotic polymorphonuclear leukocytes

    PLoS ONE, Vol. 6, Núm. 12

  5. Direct effects of type I interferons on cells of the immune system

    Clinical Cancer Research, Vol. 17, Núm. 9, pp. 2619-2627

  6. Pilot clinical trial of type 1 dendritic cells loaded with autologous tumor lysates combined with GM-CSF, pegylated IFN, and cyclophosphamide for metastatic cancer patients

    Journal of Immunology, Vol. 187, Núm. 11, pp. 6130-6142

  7. Synergistic effects of CTLA-4 blockade with tremelimumab and elimination of regulatory T lymphocytes in vitro and in vivo

    International Journal of Cancer, Vol. 129, Núm. 2, pp. 374-386

2010

  1. Delivery of immunostimulatory monoclonal antibodies by encapsulated hybridoma cells

    Cancer Immunology, Immunotherapy, Vol. 59, Núm. 11, pp. 1621-1631

  2. Treatment with anti-CD137 mAbs causes intense accumulations of liver T cells without selective antitumor immunotherapeutic effects in this organ

    Cancer Immunology, Immunotherapy, Vol. 59, Núm. 8, pp. 1223-1233

2009

  1. Clinical development of combination strategies in immunotherapy: Are we ready for more than one investigational product in an early clinical trial?

    Immunotherapy, Vol. 1, Núm. 5, pp. 845-853

  2. In vivo depletion of DC impairs the anti-tumor effect of agonistic anti-CD137 mAb

    European Journal of Immunology, Vol. 39, Núm. 9, pp. 2424-2436

  3. Influence of bevacizumab, sunitinib and sorafenib as single agents or in combination on the inhibitory effects of VEGF on human dendritic cell differentiation from monocytes

    British Journal of Cancer, Vol. 100, Núm. 7, pp. 1111-1119